NCT05705089View on ClinicalTrials.gov

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

February 1, 2023

Study Completion Date

April 1, 2023

Conditions
Left Ventricular ThrombusST Segment Elevation Myocardial Infarction
Interventions
DRUG

Rivaroxaban 15 MG

Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))

DRUG

Warfarin

Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))

Trial Locations (2)

1995614331

Rajaie Cardiovascular Medical and Research Center, Tehran

Unknown

Tehran Heart Center, Tehran

All Listed Sponsors
collaborator

Tehran Heart Center

OTHER

lead

Rajaie Cardiovascular Medical and Research Center

OTHER

NCT05705089 - Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI | Biotech Hunter | Biotech Hunter